Global Anti-Retroviral Drugs Market By Product Type (Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors) And By End-Users/Application (Hepatitis, HIV/AIDS) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-985020
  • April 2021
  • Pharmaceuticals
  • 117 Pages

Report Preview

The Anti-Retroviral Drugs Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)

The Anti-Retroviral Drugs Market has been valued at US$ xx Mn in the year 2020 and is anticipated to attain US$ xx Mn by the year 2028 along with a CAGR of xx%

Anti-Retroviral Drugs Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Anti-Retroviral Drugs market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Integrase Inhibitors, Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
Applications Hepatitis, HIV/AIDS, Herpes, Influenza, Others
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Cardionet, GE Healthcare, Abbott, AstraZeneca, Bristol-Myers-Squibb, Gilead, Cardiac Science Corp., Cardiocom, Biotelemetry, GlaxoSmithKline, Roche
 
Anti-Retroviral Drugs Market Competitive and Premeditated Analysis
In the Anti-Retroviral Drugs report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Anti-Retroviral Drugs research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Anti-Retroviral Drugs Market Segmentation Analysis:
The Anti-Retroviral Drugs market is segmented into various sections such as product types, applications as well as end users and regions. Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

Segmentation based on type includes Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Integrase Inhibitors, Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors   

The application segment includes   Hepatitis, HIV/AIDS, Herpes, Influenza, Others

Major Key Players for Global Anti-Retroviral Drugs Market:
The Anti-Retroviral Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Cardionet, GE Healthcare, Abbott, AstraZeneca, Bristol-Myers-Squibb, Gilead, Cardiac Science Corp., Cardiocom, Biotelemetry, GlaxoSmithKline, Roche
 
The Anti-Retroviral Drugs market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Regional Analysis of the Anti-Retroviral Drugs market:
The Anti-Retroviral Drugs market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

The Global segmentation of the Anti-Retroviral Drugs market:
By Type:
  • Protease Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Integrase Inhibitors
  • Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors

By Application
  • Hepatitis
  • HIV/AIDS
  • Herpes
  • Influenza
  • Others

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


 
Major Factors Included and highlighted in the Anti-Retroviral Drugs report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Anti-Retroviral Drugs market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Anti-Retroviral Drugs market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Anti-Retroviral Drugs market is included in the report.
 
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Anti-Retroviral Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Anti-Retroviral Drugs market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Anti-Retroviral Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Anti-Retroviral Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Anti-Retroviral Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Anti-Retroviral Drugs Market Snapshot
          2.1.1. Global Anti-Retroviral Drugs Market By Type,2019
               2.1.1.1.Protease Inhibitors
               2.1.1.2.Non-Nucleoside Reverse Transcriptase Inhibitors
               2.1.1.3.Integrase Inhibitors
               2.1.1.4.Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
          2.1.2. Global Anti-Retroviral Drugs Market By Application,2019
               2.1.2.1.Hepatitis
               2.1.2.2.HIV/AIDS
               2.1.2.3.Herpes
               2.1.2.4.Influenza
               2.1.2.5.Others
          2.1.3. Global Anti-Retroviral Drugs Market By End-use,2019
          2.1.4. Global Anti-Retroviral Drugs Market By Geography,2019

3. Global Anti-Retroviral Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Anti-Retroviral Drugs Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Anti-Retroviral Drugs Market Size (US$), By Type, 2018 – 2028

5. Global Anti-Retroviral Drugs Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Anti-Retroviral Drugs Market Size (US$), By Application, 2018 – 2028

6. Global Anti-Retroviral Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Anti-Retroviral Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Anti-Retroviral Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Anti-Retroviral Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Anti-Retroviral Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Anti-Retroviral Drugs Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Anti-Retroviral Drugs Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Anti-Retroviral Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Anti-Retroviral Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Anti-Retroviral Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Anti-Retroviral Drugs Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Anti-Retroviral Drugs Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Anti-Retroviral Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Anti-Retroviral Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Anti-Retroviral Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Anti-Retroviral Drugs Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Anti-Retroviral Drugs Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Anti-Retroviral Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Anti-Retroviral Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Anti-Retroviral Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Anti-Retroviral Drugs Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Anti-Retroviral Drugs Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Anti-Retroviral Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Anti-Retroviral Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Anti-Retroviral Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Anti-Retroviral Drugs Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Anti-Retroviral Drugs Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Anti-Retroviral Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Anti-Retroviral Drugs Providers
        8.4.1 Cardionet
                8.1.1 Business Description
                8.1.2 Cardionet Geographic Operations
                8.1.3 Cardionet Financial Information
                8.1.4 Cardionet Product Positions/Portfolio
                8.1.5 Cardionet Key Developments
        8.4.2 GE Healthcare
                8.2.1 Business Description
                8.2.2 GE Healthcare Geographic Operations
                8.2.3 GE Healthcare Financial Information
                8.2.4 GE Healthcare Product Positions/Portfolio
                8.2.5 GE Healthcare Key Developments
        8.4.3 Abbott
                8.3.1 Business Description
                8.3.2 Abbott Geographic Operations
                8.3.3 Abbott Financial Information
                8.3.4 Abbott Product Positions/Portfolio
                8.3.5 Abbott Key Developments
        8.4.4 AstraZeneca
                8.4.1 Business Description
                8.4.2 AstraZeneca Geographic Operations
                8.4.3 AstraZeneca Financial Information
                8.4.4 AstraZeneca Product Positions/Portfolio
                8.4.5 AstraZeneca Key Developments
        8.4.5 Bristol-Myers-Squibb
                8.5.1 Business Description
                8.5.2 Bristol-Myers-Squibb Geographic Operations
                8.5.3 Bristol-Myers-Squibb Financial Information
                8.5.4 Bristol-Myers-Squibb Product Positions/Portfolio
                8.5.5 Bristol-Myers-Squibb Key Developments
        8.4.6 Gilead
                8.6.1 Business Description
                8.6.2 Gilead Geographic Operations
                8.6.3 Gilead Financial Information
                8.6.4 Gilead Product Positions/Portfolio
                8.6.5 Gilead Key Developments
        8.4.7 Cardiac Science Corp.
                8.7.1 Business Description
                8.7.2 Cardiac Science Corp. Geographic Operations
                8.7.3 Cardiac Science Corp. Financial Information
                8.7.4 Cardiac Science Corp. Product Positions/Portfolio
                8.7.5 Cardiac Science Corp. Key Developments
        8.4.8 Cardiocom
                8.8.1 Business Description
                8.8.2 Cardiocom Geographic Operations
                8.8.3 Cardiocom Financial Information
                8.8.4 Cardiocom Product Positions/Portfolio
                8.8.5 Cardiocom Key Developments
        8.4.9 Biotelemetry
                8.9.1 Business Description
                8.9.2 Biotelemetry Geographic Operations
                8.9.3 Biotelemetry Financial Information
                8.9.4 Biotelemetry Product Positions/Portfolio
                8.9.5 Biotelemetry Key Developments
        8.4.10 GlaxoSmithKline
                8.10.1 Business Description
                8.10.2 GlaxoSmithKline Geographic Operations
                8.10.3 GlaxoSmithKline Financial Information
                8.10.4 GlaxoSmithKline Product Positions/Portfolio
                8.10.5 GlaxoSmithKline Key Developments
        8.4.11 Roche
                8.11.1 Business Description
                8.11.2 Roche Geographic Operations
                8.11.3 Roche Financial Information
                8.11.4 Roche Product Positions/Portfolio
                8.11.5 Roche Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Anti-Retroviral Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Anti-Retroviral Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Anti-Retroviral Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Anti-Retroviral Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Anti-Retroviral Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Anti-Retroviral Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Anti-Retroviral Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Anti-Retroviral Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Anti-Retroviral Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Anti-Retroviral Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Anti-Retroviral Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Anti-Retroviral Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Anti-Retroviral Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Anti-Retroviral Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Anti-Retroviral Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Anti-Retroviral Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Anti-Retroviral Drugs: Market Segmentation 
FIG. 2 Global Anti-Retroviral Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Anti-Retroviral Drugs Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Anti-Retroviral Drugs Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Anti-Retroviral Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Anti-Retroviral Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Anti-Retroviral Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Anti-Retroviral Drugs Providers, 2019
FIG. 11 Global Anti-Retroviral Drugs Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Anti-Retroviral Drugs Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Anti-Retroviral Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Anti-Retroviral Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Anti-Retroviral Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Anti-Retroviral Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Anti-Retroviral Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Anti-Retroviral Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Anti-Retroviral Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Anti-Retroviral Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Anti-Retroviral Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Anti-Retroviral Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Anti-Retroviral Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Anti-Retroviral Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Anti-Retroviral Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Anti-Retroviral Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Anti-Retroviral Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Anti-Retroviral Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Anti-Retroviral Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Anti-Retroviral Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Anti-Retroviral Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Anti-Retroviral Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Anti-Retroviral Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Anti-Retroviral Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Anti-Retroviral Drugs Market Value, By Country, 2018 – 2028
TABLE  Cardionet: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GE Healthcare: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Abbott: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers-Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Gilead: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cardiac Science Corp.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cardiocom: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biotelemetry: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Roche: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Anti-Retroviral Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Anti-Retroviral Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Anti-Retroviral Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Anti-Retroviral Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Anti-Retroviral Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Anti-Retroviral Drugs Providers, 2016
FIG.  Global Anti-Retroviral Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Protease Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Non-Nucleoside Reverse Transcriptase Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Integrase Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Anti-Retroviral Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Hepatitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global HIV/AIDS Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Herpes Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Influenza Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Anti-Retroviral Drugs Market Value, 2018 – 2028, (US$ Mn)